1. Scrip
  2. >>Focus On Asia

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

Area Attracting Investors

 
• By Dexter Jie Yan

Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.

acquisition deal
Asset acquisition helping Chinese biotechs gain traction in radiopharmaceuticals push • Source: Shutterstock

On 29 November, Shanghai-based Full-Life Technologies Limited announced it would acquire Focus-X Therapeutics, a two-year-old US biotech focusing on the development of peptide receptor radionuclide therapies.

The Chinese biotech is expanding into the radiopharmaceutical arena and its first foreign acquisition

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.